FRAT1
FRAT1 (FRAT regulator of Wnt signalling pathway 1) is a cytoplasmic member of the GSK-3-binding protein family that positively regulates Wnt signalling. UniProt lists it as proto-oncogene FRAT1; it was originally named frequently rearranged in advanced T-cell lymphomas 1. Browse Assay Genie's current range of FRAT1 research reagents below, or read on for the biology behind the target.
FRAT1 acts as a positive regulator of the Wnt signalling pathway. It associates with glycogen synthase kinase 3 (GSK-3) and inhibits GSK-3-mediated phosphorylation of beta-catenin. By doing so, the FRAT1 protein stabilises beta-catenin, which is the central effector of canonical Wnt signalling. This makes FRAT1 a useful point of study for researchers examining how GSK-3 activity is controlled within the pathway.
The FRAT1 gene encodes a cytoplasmic protein that belongs to the GSK-3-binding protein family. The mouse ortholog is Frat1, which allows the gene to be studied in murine models. The source annotations do not describe tissue expression, so this page does not make claims about where the protein is found beyond its cytoplasmic localisation.
The name reflects the gene's history: HGNC records previous names including frequently rearranged in advanced T-cell lymphomas and frequently rearranged in advanced T-cell lymphomas 1. UniProt designates the product a proto-oncogene, and the annotation suggests a role in tumour progression. FRAT1 may also collaborate with PIM1 and MYC in lymphomagenesis, which links Wnt pathway regulation to lymphoma biology.
FRAT1 positively regulates the Wnt pathway by stabilising beta-catenin through its association with GSK-3.
FRAT1 inhibits GSK-3-mediated phosphorylation of beta-catenin, making it relevant to studies of this regulatory step.
FRAT1 is described as a proto-oncogene that may play a role in tumour progression.
FRAT1 may collaborate with PIM1 and MYC in lymphomagenesis, and was first identified in advanced T-cell lymphomas.
FRAT1 positively regulates the Wnt signalling pathway. It associates with GSK-3 and inhibits GSK-3-mediated phosphorylation of beta-catenin, which stabilises beta-catenin. It may also contribute to tumour progression and lymphomagenesis.
The approved name is FRAT regulator of Wnt signalling pathway 1. Earlier names recorded by HGNC include frequently rearranged in advanced T-cell lymphomas and frequently rearranged in advanced T-cell lymphomas 1. UniProt lists the protein as proto-oncogene FRAT1.
UniProt annotates FRAT1 as a proto-oncogene that may play a role in tumour progression. It may collaborate with PIM1 and MYC in lymphomagenesis. The mouse ortholog is Frat1; check the datasheet of any product for its validated reactivity.
Wnt pathway components, GSK-3 kinases and lymphoma-associated proto-oncogenes related to FRAT1.
Gene and protein annotations from HGNC, NCBI Gene and UniProt Q92837; product specifications from Assay Genie datasheets.